Biodexa Pharmaceuticals Plc (BDRX)
| Market Cap | 3.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.17M |
| Shares Out | 2.56M |
| EPS (ttm) | -14.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,048 |
| Open | 1.380 |
| Previous Close | 1.380 |
| Day's Range | 1.370 - 1.400 |
| 52-Week Range | 1.140 - 74.000 |
| Beta | 1.16 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 16, 2025 |
About BDRX
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent g... [Read more]
News
Result of General Meeting
May 2, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipe...
Notice of General Meeting
April 17, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a p...
Preliminary Results for the Year Ended 31 December 2024
April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals ...
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter
CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. P...
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase ...
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Fa...
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as ad...
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen...
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent...
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical st...
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet med...
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceu...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Compa...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Compa...
Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Compa...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Compa...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc ("Biodexa" or "the Compa...
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival CARDIFF, UK / ACCESSWIRE / October 17, 2024 / Biodexa Pharmaceuticals PLC (NASDA...
Biodexa Announces Successful Appeal of Nasdaq Delisting
Exhibit 99.1 October 15, 2024 Biodexa Announces Successful Appeal of Nasdaq Delisting Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutic...
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with Published...
Interim results for the six months ended June 30, 2024
September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused cl...
ADR Ratio Change
September 19, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company...
Receipt of Nasdaq Delisting Determination - Plans to Appeal
August 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused cl...
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq...